JP2022525478A5 - - Google Patents

Info

Publication number
JP2022525478A5
JP2022525478A5 JP2021556493A JP2021556493A JP2022525478A5 JP 2022525478 A5 JP2022525478 A5 JP 2022525478A5 JP 2021556493 A JP2021556493 A JP 2021556493A JP 2021556493 A JP2021556493 A JP 2021556493A JP 2022525478 A5 JP2022525478 A5 JP 2022525478A5
Authority
JP
Japan
Prior art keywords
sequence
binding protein
bispecific antigen
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021556493A
Other languages
English (en)
Japanese (ja)
Other versions
JP7682797B2 (ja
JP2022525478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023986 external-priority patent/WO2020191344A1/en
Publication of JP2022525478A publication Critical patent/JP2022525478A/ja
Publication of JP2022525478A5 publication Critical patent/JP2022525478A5/ja
Priority to JP2025080864A priority Critical patent/JP7856818B2/ja
Application granted granted Critical
Publication of JP7682797B2 publication Critical patent/JP7682797B2/ja
Priority to JP2026071684A priority patent/JP2026126293A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021556493A 2019-03-20 2020-03-20 クローディン6二重特異性抗体 Active JP7682797B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025080864A JP7856818B2 (ja) 2019-03-20 2025-05-14 クローディン6二重特異性抗体
JP2026071684A JP2026126293A (ja) 2019-03-20 2026-04-23 クローディン6二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821399P 2019-03-20 2019-03-20
US62/821,399 2019-03-20
PCT/US2020/023986 WO2020191344A1 (en) 2019-03-20 2020-03-20 Claudin-6 bispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080864A Division JP7856818B2 (ja) 2019-03-20 2025-05-14 クローディン6二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2022525478A JP2022525478A (ja) 2022-05-16
JP2022525478A5 true JP2022525478A5 (cg-RX-API-DMAC10.html) 2023-03-29
JP7682797B2 JP7682797B2 (ja) 2025-05-26

Family

ID=72521273

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021556493A Active JP7682797B2 (ja) 2019-03-20 2020-03-20 クローディン6二重特異性抗体
JP2025080864A Active JP7856818B2 (ja) 2019-03-20 2025-05-14 クローディン6二重特異性抗体
JP2026071684A Pending JP2026126293A (ja) 2019-03-20 2026-04-23 クローディン6二重特異性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025080864A Active JP7856818B2 (ja) 2019-03-20 2025-05-14 クローディン6二重特異性抗体
JP2026071684A Pending JP2026126293A (ja) 2019-03-20 2026-04-23 クローディン6二重特異性抗体

Country Status (6)

Country Link
US (1) US20220177583A1 (cg-RX-API-DMAC10.html)
EP (1) EP3941944A4 (cg-RX-API-DMAC10.html)
JP (3) JP7682797B2 (cg-RX-API-DMAC10.html)
CN (1) CN114206934A (cg-RX-API-DMAC10.html)
CA (1) CA3134056A1 (cg-RX-API-DMAC10.html)
WO (1) WO2020191344A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3941946T3 (da) 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
JP7359864B2 (ja) 2019-07-10 2023-10-11 中外製薬株式会社 クローディン6結合分子およびその使用
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP4240770A1 (en) * 2020-11-06 2023-09-13 Amgen Research (Munich) GmbH Polypeptide constructs selectively binding to cldn6 and cd3
US20240150455A1 (en) * 2021-03-05 2024-05-09 Shanghai GenBase Biotechnology Co., Ltd. Anti-cldn6 antibody and use thereof
EP4305067A1 (en) * 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20240004680A (ko) * 2021-05-07 2024-01-11 센티 바이오사이언시스, 인코포레이티드 키메라 수용체 및 이의 사용 방법
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
IL309495A (en) * 2021-07-15 2024-02-01 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
JP2024532482A (ja) * 2021-09-01 2024-09-05 バイオセプター (オースト) プロプライエタリー・リミテッド 免疫活性を刺激するための方法および組成物
CA3230426A1 (en) * 2021-09-03 2023-03-09 Novarock Biotherapeutics, Ltd. Bispecific binding proteins that bind cd137 and a tumor associated antigen
JPWO2023053282A1 (cg-RX-API-DMAC10.html) * 2021-09-29 2023-04-06
KR20260005971A (ko) * 2023-04-29 2026-01-12 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 변형된 항체, 이의 항체 단편, 및 항체-약물 접합체
KR20260015262A (ko) 2023-05-25 2026-02-02 더 리전트 오브 더 유니버시티 오브 캘리포니아 암 치료를 위한 클라우딘-6 접합체의 투여량

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US581916A (en) 1897-05-04 Harvester
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
ES2165346T3 (es) 1989-09-15 2002-03-16 Res Triangle Inst Analogos de 10,11-metilendioxi-20(rs)-camptotecina y 10,11-metilendioxi-20(s)-camptotecina.
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6407115B1 (en) 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
FR2707988B1 (fr) 1993-07-21 1995-10-13 Pf Medicament Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
WO1999040942A1 (en) 1998-02-10 1999-08-19 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
JP2003530297A (ja) 1998-10-16 2003-10-14 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ, リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Vipアンタゴニストを用いる併用療法
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
EP1534674A4 (en) 2002-08-02 2007-11-28 Immunogen Inc CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE
EP1542723B1 (en) 2002-08-16 2011-02-23 ImmunoGen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
WO2004033036A2 (en) 2002-10-04 2004-04-22 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
EP3026064B1 (en) * 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
IL282953B2 (en) * 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
CN108431026B (zh) 2015-11-02 2023-02-17 豪夫迈·罗氏有限公司 制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
SG11202002114RA (en) * 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer

Similar Documents

Publication Publication Date Title
JP7773528B2 (ja) 抗cd28組成物
JP2022541435A5 (cg-RX-API-DMAC10.html)
Godar et al. Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
JP5851419B2 (ja) ヘテロダイマー結合タンパク質およびその使用
JP7854121B2 (ja) 微小ガイダンス及びナビゲーションコントロール(miniGNC)抗体様タンパク質、その製造方法及び使用方法
JP2023516004A5 (cg-RX-API-DMAC10.html)
EP4508085A1 (en) Antibodies that bind pd-l1, pd-l2 and/or cd28
CN113150156B (zh) 抗tigit抗体及其用途
CN115279412A (zh) 偶联脂肪酸分子的抗体及其用途
US20230303720A1 (en) Formulations for protein therapeutics
JP7592712B2 (ja) ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
JP2023516941A5 (cg-RX-API-DMAC10.html)
JP2024541476A5 (cg-RX-API-DMAC10.html)
JP2026027248A (ja) 抗原結合分子およびその使用
CA3228641A1 (en) Fap/cd40 binding molecule and medicinal use thereof
JP2026514029A (ja) 抗cd28×抗trop2抗体
JP2025512953A5 (cg-RX-API-DMAC10.html)
JP2026510833A (ja) 抗cd28組成物
US20240124574A1 (en) Bispecific Antibodies with Charge Pairs and Uses Thereof
TW202241967A (zh) 基於茚地那韋的化學二聚化t細胞銜接器組成物
US20250101104A1 (en) Bispecific molecule with tunable affinity to a targeted antigen
JP2024508597A5 (cg-RX-API-DMAC10.html)
HK40082596A (en) Antibodies conjugated with fatty acid molecules and uses thereof
Kiprijanov Bispecific antibodies and immune therapy targeting